Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
In vivo CAR T cell generation to treat cancer and autoimmune disease.
Journal: Science (New York, N.Y.)
Published: June 19, 2025
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
Journal: Journal of neurology
Published: March 16, 2022
Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.
Journal: Molecular cancer therapeutics
Published: October 07, 2020
Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis.
Journal: Drug design, development and therapy
Published: May 24, 2019
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: September 01, 2018
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
Journal: The New England journal of medicine
Published: July 05, 2018
An aggressive form of transthyretin amyloidosis.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: April 25, 2017
A Case-Control Study to Determine the Prognostic Features of Salivary Epithelial Cells in Periodontitis.
Journal: JDR clinical and translational research
Published: October 01, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026